Drug Profile
Research programme: bispecific antibodies - Gilead Sciences
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Genmab; Gilead Sciences
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections